Trial Profile

A Randomized, Controlled, Multicenter, Open-label Study to Investigate the Efficacy and Safety of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone-Sensitive Prostate Cancer, Assessed by PSMA-PET With an Observational Cohort

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 02 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Apalutamide (Primary) ; Goserelin (Primary) ; Leuprorelin (Primary) ; Triptorelin (Primary)
Indications Adenocarcinoma; Prostate cancer
Focus Registrational; Therapeutic Use
Acronyms PRIMORDIUM
Sponsors Janssen-Cilag

17 Jul 2024 Status changed from recruiting to active, no longer recruiting.
26 Mar 2024 Planned End Date changed from 28 Jan 2030 to 27 Aug 2029.
26 Mar 2024 Planned primary completion date changed from 28 Jan 2030 to 27 Aug 2029.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com